A body of evidence indicates that regulations of aberrant NF-κB and the signaling pathways that control its activity are involved in cancer development and progression, as well as in drug resistance, especially during chemotherapy and radiotherapy [11]–[14]. Here, NFKB1 is linked to cancer.